Fig. 2: Forest plot of RFS with immune-subset signatures in the NCCTG N9831 with chemotherapy-only arm (AC–T) in blue and sequential (AC–T–H) or concurrent trastuzumab arm (AC–TH) in red. | npj Breast Cancer

Fig. 2: Forest plot of RFS with immune-subset signatures in the NCCTG N9831 with chemotherapy-only arm (AC–T) in blue and sequential (AC–T–H) or concurrent trastuzumab arm (AC–TH) in red.

From: Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Fig. 2

The HR on the forest plots was from multivariate models adjusting for age, nodal status, ER/PR status, tumor size, and tumor grade. The size of the box in the forest plots represents the precision (standard error) of the estimates.

Back to article page